 SOUTH SAN FRANCISCO, Calif., Dec. 01, 2021 GLOBE NEWSWIRE -- Allogene Therapeutics, Inc. Nasdaq: ALLO, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T AlloCAR TTM therapies for cancer, today announced that management will host a conference call to review data to be presented at the American Society of Hematology Annual Meeting from the ALPHA and ALPHA2 Phase 1 trials in relapsedrefractory non-Hodgkin lymphoma and the UNIVERSAL Phase 1 trial in relapsedrefractory multiple myeloma on December 13, 2021 at 1:30 PM Pacific Time4:30 PM Eastern Time. 